Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Aspirin or Clopidogrel as Monotherapy after 12 month DAPT

Original Title: Clopidogrel versus Aspirin as an Antiplatelet Monotherapy after 12-Month Dual-Antiplatelet Therapy in the Era of Drug-Eluting Stents. Reference: Taek Kyu Park et al. Circ Cardiovasc Interv. 2016 Jan;9(1):e002816.

Courtesy of Dr. José Amadeo Guillermo Álvarez.

The use of dual antiplatelet therapy (DAPT) over 12 months after hospitalization for acute myocardial infarction (AMI) or drug eluting stent implantation (DES) could, in some subgroups of patients, reduce ischemic events at the expense of a higher risk of bleeding. However, no evidence supports a sound recommendation over the best antiplatelet after a 12 month DAPT treatment. This is an observational study carried out between 2003 and 2010 that compares the clinical evolution of 3243 patients receiving DES and 12 month DAPT. Patients were divided in two groups, those prescribed aspirin (n=2472) and those prescribed clopidogrel (n=771). Patients in the clopidogrel group had more comorbidities and more complex lesions than those in the aspirin group.

After a 36 month follow up, clopidogrel monotherapy resulted in a significant reduction of the final end point, the combination of death, AMI or stroke (aspirin vs. clopidogrel 3.8% vs 2.6% HR 0.54; CI 95% 0.32-0.92; p=0.02) and of cardiac mortality (aspirin vs. clopidogrel 1.4% vs 0.5%; HR 0.31; CI 95% 0.11-0.93; p=0.04). Major bleeding (TIMI) was similar in both groups (0.9% vs 1.3%; HR 1.03; CI 95% 0.46-2.32: p=0.95).

Conclusion
After 12 months of dual antiplatelet therapy, clopidogrel monotherapy instead of aspirin could be associated to a lower risk of ischemic events in patients receiving a DES.

Editorial Comment
We should bear in mind this registry did not randomize the administered drugs. Even though the population in the aspirin group has characteristics of lower clinical and angiographic risk, most of these patients received first generation DES (sirolimus or paclitaxel, 64.3%), whereas most of patients in the clopidogrel group received everolimus or zotarolimus eluting stents (68.2%), and even though the authors do mention the logistic regression analysis found no correlation between primary end point and type of stent or time of PCI, the results should take into account the number of patients.

The hypothesis stating that clopidogrel is superior to aspirin after post DES 12 month DAPT, calls for further analysis in a larger prospective, randomized study.

Courtesy of Dr. José Amadeo Guillermo Álvarez.

More articles by this author

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

EuroPCR 2026 | Could clopidogrel replace aspirin as monotherapy after PCI?

This presentation, delivered during EuroPCR 2026, analyzed the clinical outcomes of clopidogrel monotherapy versus aspirin in patients who remained event-free for 12 months after...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...